| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $992,575 ) |
| | 2025 | 2025 | BIOVINC, LLC | 2265 E FOOTHILL BLVD | PASADENA | CA | 91107-3658 | LOS ANGELES | USA | R44AI175069 | A Novel Bone Targeted Antibiotic Therapy for the Treatment of Infected Fractures | 003 | 3 | NIH | 3/28/2025 | $992,575 |
| | 2025 | 2024 | BIOVINC, LLC | 2265 E FOOTHILL BLVD | PASADENA | CA | 91107-3658 | LOS ANGELES | USA | R44AI175069 | A Novel Bone Targeted Antibiotic Therapy for the Treatment of Infected Fractures | 000 | 2 | NIH | 12/30/2024 | $0 |
| | 2025 | 2024 | BIOVINC, LLC | 2265 E FOOTHILL BLVD | PASADENA | CA | 91107-3658 | LOS ANGELES | USA | R44AI175069 | A Novel Bone Targeted Antibiotic Therapy for the Treatment of Infected Fractures | 001 | 2 | NIH | 1/10/2025 | $0 |
| | 2025 | 2023 | BIOVINC, LLC | 2265 E FOOTHILL BLVD | PASADENA | CA | 91107-3658 | LOS ANGELES | USA | R44AI175069 | A Novel Bone Targeted Antibiotic Therapy for the Treatment of Infected Fractures | 002 | 1 | NIH | 2/10/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $978,787 ) |
| | 2024 | 2024 | BIOVINC, LLC | 2265 E FOOTHILL BLVD | PASADENA | CA | 91107-3658 | LOS ANGELES | USA | R44AI175069 | A Novel Bone Targeted Antibiotic Therapy for the Treatment of Infected Fractures | 000 | 2 | NIH | 4/22/2024 | $978,787 |
| | 2024 | 2022 | BIOVINC, LLC | 2265 E FOOTHILL BLVD | PASADENA | CA | 91107-3658 | LOS ANGELES | USA | R44AI125060 | Bone targeted delivery of an antimicrobial drug for osteomyelitis therapy | 000 | 4 | NIH | 8/1/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $296,779 ) |
| | 2023 | 2023 | BIOVINC, LLC | 1421 STATE ST STE B | SANTA BARBARA | CA | 93101-2507 | SANTA BARBARA | USA | R44AI175069 | A Novel Bone Targeted Antibiotic Therapy for the Treatment of Infected Fractures | 000 | 1 | NIH | 3/3/2023 | $296,779 |
|
| Issue Date FY: 2022 ( Subtotal = $988,634 ) |
| | 2022 | 2022 | BIOVINC, LLC | 1421 STATE ST STE B | SANTA BARBARA | CA | 93101-2507 | SANTA BARBARA | USA | R44AI125060 | Bone targeted delivery of an antimicrobial drug for osteomyelitis therapy | 000 | 4 | NIH | 12/10/2021 | $988,634 |
| | 2022 | 2019 | BIOVINC, LLC | 1421 STATE ST STE B | SANTA BARBARA | CA | 93101-2507 | SANTA BARBARA | USA | R41CA235996 | Bone Metastasis Specific 18F PET Imaging Probe for Breast Cancer | 000 | 1 | NIH | 6/9/2022 | $0 |
| | 2022 | 2018 | BIOVINC, LLC | 1421 STATE ST STE B | SANTA BARBARA | CA | 93101-2507 | SANTA BARBARA | USA | R44DE025524 | Competitive Equilibrium-based Displacement of Bisphosphonates as Novel Therapeutic Approach for BRONJ | 000 | 3 | NIH | 7/7/2022 | $0 |
| | 2022 | 2018 | BIOVINC, LLC | 1421 STATE ST STE B | SANTA BARBARA | CA | 93101-2507 | SANTA BARBARA | USA | R43AR073727 | Bone targeted antimicrobials for the treatment of diabetic foot related infections and osteomyelitis | 000 | 1 | NIH | 12/1/2021 | $0 |
| | 2022 | 2018 | BIOVINC, LLC | 1421 STATE ST STE B | SANTA BARBARA | CA | 93101-2507 | SANTA BARBARA | USA | R42DE025789 | Bone targeted antimicrobials for biofilm-mediated osteolytic infection treatment | 000 | 3 | NIH | 5/9/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $975,586 ) |
| | 2021 | 2021 | BIOVINC, LLC | 1421 STATE ST STE B | SANTA BARBARA | CA | 93101-2507 | SANTA BARBARA | USA | R44AI125060 | Bone targeted delivery of an antimicrobial drug for osteomyelitis therapy | 000 | 3 | NIH | 12/14/2020 | $975,586 |
| | 2021 | 2019 | BIOVINC, LLC | 1421 STATE ST STE B | SANTA BARBARA | CA | 93101-2507 | SANTA BARBARA | USA | R41CA235996 | Bone Metastasis Specific 18F PET Imaging Probe for Breast Cancer | 000 | 1 | NIH | 3/11/2021 | $0 |
| | 2021 | 2018 | BIOVINC, LLC | 1421 STATE ST STE B | SANTA BARBARA | CA | 93101-2507 | SANTA BARBARA | USA | R44DE025524 | Competitive Equilibrium-based Displacement of Bisphosphonates as Novel Therapeutic Approach for BRONJ | 000 | 3 | NIH | 1/20/2021 | $0 |
| | 2021 | 2018 | BIOVINC, LLC | 1421 STATE ST STE B | SANTA BARBARA | CA | 93101-2507 | SANTA BARBARA | USA | R44DE025524 | Competitive Equilibrium-based Displacement of Bisphosphonates as Novel Therapeutic Approach for BRONJ | 001 | 3 | NIH | 1/21/2021 | $0 |
| | 2021 | 2016 | BIOVINC, LLC | 1421 STATE ST STE B | SANTA BARBARA | CA | 93101-2507 | SANTA BARBARA | USA | R41DE025789 | Bone targeted antimicrobials for biofilm-mediated osteolytic infection treatment | 000 | 1 | NIH | 6/12/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $999,300 ) |
| | 2020 | 2020 | BIOVINC, LLC | 1421 STATE ST STE B | SANTA BARBARA | CA | 93101-2507 | SANTA BARBARA | USA | R44AI125060 | Bone targeted delivery of an antimicrobial drug for osteomyelitis therapy | 000 | 2 | NIH | 1/13/2020 | $999,300 |
| | 2020 | 2018 | BIOVINC, LLC | 1421 STATE ST STE B | SANTA BARBARA | CA | 93101-2507 | SANTA BARBARA | USA | R44DE025524 | Competitive Equilibrium-based Displacement of Bisphosphonates as Novel Therapeutic Approach for BRONJ | 000 | 3 | NIH | 11/13/2019 | $0 |
| | 2020 | 2018 | BIOVINC, LLC | 1421 STATE ST STE B | SANTA BARBARA | CA | 93101-2507 | SANTA BARBARA | USA | R44DE025524 | Competitive Equilibrium-based Displacement of Bisphosphonates as Novel Therapeutic Approach for BRONJ | 002 | 3 | NIH | 2/6/2020 | $0 |
| | 2020 | 2018 | BIOVINC, LLC | 1421 STATE ST STE B | SANTA BARBARA | CA | 93101-2507 | SANTA BARBARA | USA | R44DE025524 | Competitive Equilibrium-based Displacement of Bisphosphonates as Novel Therapeutic Approach for BRONJ | 001 | 3 | NIH | 2/6/2020 | $0 |
| | 2020 | 2018 | BIOVINC, LLC | 1421 STATE ST STE B | SANTA BARBARA | CA | 93101-2507 | SANTA BARBARA | USA | R43AR073727 | Bone targeted antimicrobials for the treatment of diabetic foot related infections and osteomyelitis | 000 | 1 | NIH | 6/4/2020 | $0 |
| | 2020 | 2018 | BIOVINC, LLC | 1421 STATE ST STE B | SANTA BARBARA | CA | 93101-2507 | SANTA BARBARA | USA | R42DE025789 | Bone targeted antimicrobials for biofilm-mediated osteolytic infection treatment | 000 | 3 | NIH | 7/17/2020 | $0 |
| | 2020 | 2016 | BIOVINC, LLC | 1421 STATE ST STE B | SANTA BARBARA | CA | 93101-2507 | SANTA BARBARA | USA | R43AI125060 | Bone targeted delivery of an antimicrobial drug for osteomyelitis therapy | 000 | 1 | NIH | 12/10/2019 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $225,000 ) |
| | 2019 | 2019 | BIOVINC, LLC | 1421 STATE ST STE B | SANTA BARBARA | CA | 93101-2507 | SANTA BARBARA | USA | R41CA235996 | Bone Metastasis Specific 18F PET Imaging Probe for Breast Cancer | 000 | 1 | NIH | 8/16/2019 | $225,000 |
|
| Issue Date FY: 2018 ( Subtotal = $2,415,987 ) |
| | 2018 | 2018 | BIOVINC, LLC | 1421 STATE ST STE B | SANTA BARBARA | CA | 93101-2507 | SANTA BARBARA | USA | R44DE025524 | Competitive Equilibrium-based Displacement of Bisphosphonates as Novel Therapeutic Approach for BRONJ | 001 | 3 | NIH | 7/31/2018 | $691,832 |
| | 2018 | 2018 | BIOVINC, LLC | 1421 STATE ST STE B | SANTA BARBARA | CA | 93101-2507 | SANTA BARBARA | USA | R44DE025524 | Competitive Equilibrium-based Displacement of Bisphosphonates as Novel Therapeutic Approach for BRONJ | 000 | 3 | NIH | 2/13/2018 | $749,155 |
| | 2018 | 2018 | BIOVINC, LLC | 1421 STATE ST STE B | SANTA BARBARA | CA | 93101-2507 | SANTA BARBARA | USA | R43AR073727 | Bone targeted antimicrobials for the treatment of diabetic foot related infections and osteomyelitis | 000 | 1 | NIH | 6/12/2018 | $225,000 |
| | 2018 | 2018 | BIOVINC, LLC | 1421 STATE ST STE B | SANTA BARBARA | CA | 93101-2507 | SANTA BARBARA | USA | R42DE025789 | Bone targeted antimicrobials for biofilm-mediated osteolytic infection treatment | 000 | 3 | NIH | 8/16/2018 | $750,000 |
| | 2018 | 2016 | BIOVINC, LLC | 1421 STATE ST STE B | SANTA BARBARA | CA | 93101-2507 | SANTA BARBARA | USA | R43AI125060 | Bone targeted delivery of an antimicrobial drug for osteomyelitis therapy | 000 | 1 | NIH | 7/6/2018 | $0 |
| | 2018 | 2015 | BIOVINC, LLC | 1421 STATE ST STE B | SANTA BARBARA | CA | 93101-2507 | SANTA BARBARA | USA | R43DE025524 | Competitive Equilibrium-based Displacement of Bisphosphonates as Novel Therapeutic Approach for BRONJ | 000 | 1 | NIH | 1/30/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $1,490,777 ) |
| | 2017 | 2017 | BIOVINC, LLC | 1421 STATE ST STE B | SANTA BARBARA | CA | 93101-2507 | SANTA BARBARA | USA | R42DE025789 | Bone targeted antimicrobials for biofilm-mediated osteolytic infection treatment | 000 | 2 | NIH | 9/1/2017 | $750,000 |
| | 2017 | 2017 | BIOVINC, LLC | 1421 STATE ST STE B | SANTA BARBARA | CA | 93101-2507 | SANTA BARBARA | USA | R44DE025524 | Competitive Equilibrium-based Displacement of Bisphosphonates as Novel Therapeutic Approach for BRONJ | 000 | 2 | NIH | 3/15/2017 | $740,777 |
| | 2017 | 2015 | BIOVINC, LLC | 1421 STATE ST STE B | SANTA BARBARA | CA | 93101-2507 | SANTA BARBARA | USA | R43AR067021 | Novel Bisphosphonate 18F-PET and PET/optical Dual Modality Probes for Rheumatoid Arthritis Imaging | 000 | 1 | NIH | 8/29/2017 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $330,770 ) |
| | 2016 | 2016 | BIOVINC LLC | 1421 STATE STREET | SANTA BARBARA | CA | 93101 | SANTA BARBARA | USA | R43AI125060 | Bone targeted delivery of an antimicrobial drug for osteomyelitis therapy | 000 | 1 | NIH | 6/22/2016 | $180,807 |
| | 2016 | 2016 | BIOVINC LLC | 1421 STATE STREET | SANTA BARBARA | CA | 93101 | SANTA BARBARA | USA | R41DE025789 | Bone targeted antimicrobials for biofilm-mediated osteolytic infection treatment | 000 | 1 | NIH | 1/8/2016 | $149,963 |
|
| Issue Date FY: 2015 ( Subtotal = $374,997 ) |
| | 2015 | 2015 | BIOVINC LLC | 1421 STATE STREET | SANTA BARBARA | CA | 93101 | SANTA BARBARA | USA | R43DE025524 | Competitive Equilibrium-based Displacement of Bisphosphonates as Novel Therapeutic Approach for BRONJ | 000 | 1 | NIH | 8/21/2015 | $150,000 |
| | 2015 | 2015 | BIOVINC LLC | 1421 STATE STREET | SANTA BARBARA | CA | 93101 | SANTA BARBARA | USA | R43AR067021 | Novel Bisphosphonate 18F-PET and PET/optical Dual Modality Probes for Rheumatoid Arthritis Imaging | 000 | 1 | NIH | 4/21/2015 | $224,997 |
|
|
